A conversation with Chris Lipinski

Chris Lipinski, author of the 1997 'rule of five',¹ believes that although the rule has altered medicinal chemistry for oral small molecule drugs, predicting the behavior of newer biologics might not be far off, and optimization of RNA or protein delivery could be the opportunity for the next big breakthrough in computer-based predictions.

The rule of five, developed while Lipinski was a senior research fellow at Pfizer Inc., outlines four simple criteria to help design orally available drugs. SciBX talked with Lipinski, now scientific advisor at Melior Discovery Inc., to hear his thoughts on the impact of the rule of five and how he thinks current predictive approaches might advance drug design...